Related Experiment Video
Updated: May 19, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
The management of pediatric multiple sclerosis
E Ann Yeh1, Bianca Weinstock-Guttman
1Demyelinating Disorders Program, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. ann.yeh@sickkids.ca
Journal of Child Neurology
|August 24, 2012
Summary
Disease-modifying therapies can prevent disability in pediatric multiple sclerosis (MS). This review covers acute relapse treatments and long-term management strategies for children and adolescents with relapsing-remitting MS.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Pediatric-onset multiple sclerosis (MS) presents unique challenges in management and treatment.
- Early intervention is crucial for preventing long-term disability in young MS patients.
- Relapsing-remitting MS is the predominant form in children and adolescents, accounting for 99% of cases.
Purpose of the Study:
- To review current literature on therapies for pediatric-onset multiple sclerosis (MS).
- To discuss disease-modifying therapies (DMTs) for preventing relapses and slowing progression in pediatric MS.
- To explore future directions for managing cognitive decline, fatigue, and depression in this population.
Main Methods:
- Literature review of available studies on pediatric MS management.
- Focus on therapies for acute exacerbations and DMTs.
- Inclusion of symptomatic interventions for associated conditions.
Main Results:
- Disease-modifying therapies are key to preventing disability in pediatric MS.
- Current literature supports the use of specific DMTs to manage relapsing-remitting MS in children and adolescents.
- Symptomatic treatments for cognitive and mood disturbances are an area for future research.
Conclusions:
- Effective management of pediatric MS involves prompt treatment of acute relapses and long-term use of DMTs.
- Preventing disability progression is achievable with appropriate therapeutic strategies.
- Further research is needed to optimize symptomatic interventions for the holistic well-being of young MS patients.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...